Augmenting reference pricing of pharmaceuticals in New Zealand with strategic cross-product agreements

PharmacoEconomics

Volumn 19, Issue 4, 2001, Pages 365-377

  Woodfield, A ^a  

^a UNIVERSITY OF CANTERBURY   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BENAZEPRIL; CAPTOPRIL; CERIVASTATIN; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; QUINAPRIL; SIMVASTATIN;

COMPETITION; COST CONTROL; DRUG COST; DRUG MANUFACTURE; DRUG MARKETING; HUMAN; HYPERCHOLESTEROLEMIA; NEW ZEALAND; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW;

EID: 0035053064     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200119040-00004     Document Type: Review

References (25)

1. Managing pharmaceutical expenditure while increasing access: The Pharmaceutical Management Agency (PHARMAC) experience
2. Review of the literature on reference pricing
3. Pharmaceutical reference prices: How do they work in practice?
4. Reference pricing: Efficient insurance design or monopsony free riding?
5. A review of clinical trials comparing HMG-CoA reductase inhibitors
6. The impact of reference pricing on clinical lipid control
7. PHARMAC and statins
8. PHARMAC and statins
9. Increased thrombotic vascular events after change of statin
10. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia
11. Clinical positioning of HM-CoA reductase inhibitors in lipid management protocols
12. The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients
13. Price discrimination for pharmaceuticals: Welfare effects in the US and the EU